What is the 13F Pro Quality Score for TRAW?

13F Pro ranks Traws Pharma, Inc. (TRAW) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View TRAW's current score at https://13fpro.ai/company/TRAW (free sign-up required for the full ranking).

Where does 13F Pro source TRAW data?

All Traws Pharma, Inc. fundamentals and ownership data come directly from SEC EDGAR. Traws Pharma, Inc. files with the SEC under CIK 1130598. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is TRAW in?

Traws Pharma, Inc. (TRAW) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is TRAW research updated on 13F Pro?

TRAW's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Traws Pharma, Inc.(TRAW)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1130598 TRAW stock profile & AI dashboard →

13F Pro Quality Score

29.7/100

Rank #2,520 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why TRAW Scores 30/100

exact factor attribution · 2026-09-11

TRAW's composite is driven by revenue growth and institutional flow, held back by scale and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+9.6 pts

98th pct

Institutional flow

+1.2 pts

74th pct

Earnings quality

-1.9 pts

31th pct

Shareholder dilution

-1.9 pts

11th pct

Earnings growth

-2.2 pts

5th pct

Capital efficiency

-4.8 pts

2th pct

Profitability

-6.6 pts

6th pct

Free cash flow

-6.7 pts

6th pct

Scale

-6.9 pts

4th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

TRAW Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Traws Pharma, Inc. (TRAW), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TRAW at 29.7/100 on a 32-signal composite quality model, placing it at rank #2,520 of 2,962 stocks — the bottom half of the AI-ranked universe. Top institutional holders of TRAW by reported 13-F value include ORBIMED ADVISORS, Ally Bridge Group (NY), ADAGE CAPITAL PARTNERS GP, L.L.C., based on the most recent SEC filings. TRAW trades on the Nasdaq exchange and files with the SEC under CIK 1130598. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TRAW daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Traws Pharma, Inc. directly from SEC EDGAR. Traws Pharma, Inc.'s 13F Pro composite quality score has ranged between 7 and 31 since 2026, currently 29.7 — an improving long-term trajectory across 8 quarterly and live scoring snapshots.

Net Income

Q2 2026

$-3.1M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+1134.5% YoY

$2.8MFY 2025

FY22 $226.0KFY23 $226.0KFY24 $226.0KFY25 $2.8M

Net Income

+105.5% YoY

$9.2MFY 2025

FY22 $-19.0MFY23 $-18.9MFY24 $-166.5MFY25 $9.2M

Operating Income

+87.4% YoY

$-17.9MFY 2025

FY22 $-19.6MFY23 $-20.3MFY24 $-142.4MFY25 $-17.9M

EPS (Diluted)

+102.3% YoY

$0.82FY 2025

FY22 $-0.91FY23 $-22.57FY24 $-35.21FY25 $0.82

Total Assets

-57.5% YoY

$10.6MFY 2025

FY22 $39.4MFY23 $22.7MFY24 $25.0MFY25 $10.6M

Op. Cash Flow

+39.0% YoY

$-18.2MFY 2025

FY22 $-16.3MFY23 $-17.9MFY24 $-29.8MFY25 $-18.2M

Free Cash Flow

+37.9% YoY

$-20.8MFY 2025

FY22 —FY23 $-17.9MFY24 $-33.4MFY25 $-20.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$2.8M +1134.5%	$226.0K +0.0%	$226.0K +0.0%	$226.0K +0.0%	$226.0K -2.2%	$231.0K
Net Income	$9.2M +105.5%	$-166.5M -778.8%	$-18.9M +0.1%	$-19.0M -17.3%	$-16.2M +35.8%	$-25.2M
Operating Income	$-17.9M +87.4%	$-142.4M -601.4%	$-20.3M -3.4%	$-19.6M -19.0%	$-16.5M +34.0%	$-25.0M
EPS (Diluted)	$0.82 +102.3%	$-35.21 -56.0%	$-22.57 -2380.2%	$-0.91 +5.2%	$-0.96 +55.8%	$-2.17
Total Assets	$10.6M -57.5%	$25.0M +10.0%	$22.7M -42.4%	$39.4M -29.0%	$55.5M +177.6%	$20.0M
Operating Cash Flow	$-18.2M +39.0%	$-29.8M -66.1%	$-17.9M -10.1%	$-16.3M +16.4%	$-19.5M +15.5%	$-23.1M
Free Cash Flow	$-20.8M +37.9%	$-33.4M -86.3%	$-17.9M	—	—	$-23.1M

Get alerted when TRAW's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Traws Pharma, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of TRAW

ORBIMED ADVISORS LLC
$1.0M1,203,260 sh
Ally Bridge Group (NY) LLC
$663.0K786,236 sh
ADAGE CAPITAL PARTNERS GP, L.L.C.
$615.6K730,000 sh
ADAR1 Capital Management, LLC
$504.1K597,729 sh
Lynx1 Capital Management LP
$471.8K559,470 sh
Ikarian Capital, LLC
$403.2K478,142 sh
SPHERA FUNDS MANAGEMENT LTD.
$336.0K398,486 sh
VANGUARD CAPITAL MANAGEMENT LLC
$278.2K330,049 sh
JANE STREET GROUP, LLC
$182.2K216,006 sh
Alyeska Investment Group, L.P.
$138.6K164,376 sh

Fund	Value	Shares
ORBIMED ADVISORS LLC	$1.0M	1,203,260
Ally Bridge Group (NY) LLC	$663.0K	786,236
ADAGE CAPITAL PARTNERS GP, L.L.C.	$615.6K	730,000
ADAR1 Capital Management, LLC	$504.1K	597,729
Lynx1 Capital Management LP	$471.8K	559,470
Ikarian Capital, LLC	$403.2K	478,142
SPHERA FUNDS MANAGEMENT LTD.	$336.0K	398,486
VANGUARD CAPITAL MANAGEMENT LLC	$278.2K	330,049
JANE STREET GROUP, LLC	$182.2K	216,006
Alyeska Investment Group, L.P.	$138.6K	164,376

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put TRAW on your watchlist

Track score changes the day Traws Pharma, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is TRAW a good stock to buy?

13F Pro's AI-powered analysis of Traws Pharma, Inc. (TRAW) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TRAW are available on the TRAW stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. TRAW is classified as a small company.

Which hedge funds own TRAW?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TRAW. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Traws Pharma, Inc.'s investment landscape.